Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Brutsche

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Respiration; International Review of Thoracic Diseases|April 23, 2023
Swiss Hypersensitivity Pneumonitis Exposure Questionnaire: A Regionally Adapted and Easy-To-Use Aide for Patients and CliniciansSusanne Pohle, Sabina A Guler, Katrin E Hostettler, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Respiration; International Review of Thoracic Diseases|March 27, 2017
Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and TreatmentManuela Funke-Chambour, Andrea Azzola, Dan Adler, et al.
American Journal of Respiratory and Critical Care Medicine|July 15, 2006
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvementRobert P Baughman, Marjolein Drent, Mani Kavuru, et al.
Respiration; International Review of Thoracic Diseases|December 23, 2021
Prediction of Acute COPD Exacerbation in the Swiss Multicenter COPD Cohort Study (TOPDOCS) by Clinical Parameters, Medication Use, and Immunological BiomarkersSimona Tabea Huebner, Simona Henny, Stéphanie Giezendanner, et al.
Swiss Medical Weekly|January 24, 2022
Sarcoidosis - a multisystem diseaseDaniel P Franzen, Martin Brutsche, Jakob Nilsson, et al.
Trials|September 20, 2022
Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trialMaria Boesing, Kristin Abig, Michael Brändle, et al.
The European Respiratory Journal|January 9, 2021
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung studySabina A Guler, Lukas Ebner, Catherine Aubry-Beigelman, et al.
Respiration; International Review of Thoracic Diseases|December 25, 2022
Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung StudyAlexandra Lenoir, Andreas Christe, Lukas Ebner, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Respiration; International Review of Thoracic Diseases|April 23, 2023
Swiss Hypersensitivity Pneumonitis Exposure Questionnaire: A Regionally Adapted and Easy-To-Use Aide for Patients and CliniciansSusanne Pohle, Sabina A Guler, Katrin E Hostettler, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Respiration; International Review of Thoracic Diseases|March 27, 2017
Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and TreatmentManuela Funke-Chambour, Andrea Azzola, Dan Adler, et al.
American Journal of Respiratory and Critical Care Medicine|July 15, 2006
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvementRobert P Baughman, Marjolein Drent, Mani Kavuru, et al.
Respiration; International Review of Thoracic Diseases|December 23, 2021
Prediction of Acute COPD Exacerbation in the Swiss Multicenter COPD Cohort Study (TOPDOCS) by Clinical Parameters, Medication Use, and Immunological BiomarkersSimona Tabea Huebner, Simona Henny, Stéphanie Giezendanner, et al.
Swiss Medical Weekly|January 24, 2022
Sarcoidosis - a multisystem diseaseDaniel P Franzen, Martin Brutsche, Jakob Nilsson, et al.
Trials|September 20, 2022
Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trialMaria Boesing, Kristin Abig, Michael Brändle, et al.
The European Respiratory Journal|January 9, 2021
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung studySabina A Guler, Lukas Ebner, Catherine Aubry-Beigelman, et al.
Respiration; International Review of Thoracic Diseases|December 25, 2022
Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung StudyAlexandra Lenoir, Andreas Christe, Lukas Ebner, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Pageof 8